MedTrace Logo

ABA-101 in Participants With Progressive Multiple Sclerosis

NCT06566261 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-07-03

No results posted yet for this study

Summary

This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis.

It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.

Conditions

Interventions

BIOLOGICAL

ABA-101

ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy

Sponsors & Collaborators

  • Abata Therapeutics

    lead INDUSTRY

Principal Investigators

  • Samantha Singer, President and CEO, Abata Therapeutics, MS MBA · Abata Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-11
Primary Completion
2026-02-28
Completion
2027-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06566261 on ClinicalTrials.gov